ReviewDrug discovery today2025
Improving B-cell epitope prediction.
Review in Drug discovery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PatchEpi: patch-aware equivariant learning improves structure-based epitope prediction.Bioinformatics (Oxford, England) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The prediction of antibody binding residues of an antigen is essential for understanding the immune response mechanisms and advancing antibody therapeutics. By definition, each epitope is the binding site of a specific antibody; however, many prediction methods are antibody-agnostic, and thus need only the structure of the antigen. Antibody-specific methods also require either the structure or models of the antibody, and are generally based on docking or co-folding algorithms. Machine learning methods have been improved substantially during the last few years, resulting in new approaches to epitope prediction. We evaluate some popular methods and show that combining AlphaFold 3 with the epitope prediction program AbEMap yields substantially better results than any of the other methods tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.